To evaluate whether TRAIL’s pro-cancer immunomodulatory role would be reflected in cancer patient-derived gene expression data, we subjected RNA sequencing (RNA-seq) data from a cohort of 489 lung adenocarcinoma (LUAD) patients (Cancer Genome Atlas Research Network, 2014), obtained from the Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/), to bioinformatic coexpression analysis focusing on immune cell markers and cytokines (Table S2). Here, TNFSF10 is linked to cancer.